† Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Commission. * Indicates, in this 2018 Form 10-K, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries.  Abilify  is a trademark of Otsuka Pharmaceutical Co., Ltd.;  Atripla, Truvada  and  Tybost  are trademarks of Gilead Sciences, Inc.; Avapro/Avalide  (known in the EU as  Aprovel/Karvea ) and  Plavix  are trademarks of Sanofi;  Byetta  is a trademark of Amylin Pharmaceuticals, LLC;  ENHANZE  is a trademark of Halozyme, Inc.;  Erbitux  is a trademark of ImClone LLC;  Farxiga  and  Onglyza  are trademarks of AstraZeneca AB;  Gleevec  is a trademark of Novartis AG;  Keytruda  is a trademark of Merck Sharp & Dohme Corp.;  Pomalyst  and  Revlimid  are trademarks of Celgene Corporation; and  Prostvac  is a trademark of BN ImmunoTherapeutics Inc. and/or one of its affiliates. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries. 113 21 Subsidiaries of the Registrant (filed herewith). E-21-1 23 Consent of Deloitte & Touche LLP (filed herewith). E-23-1 31a. Section 302 Certification Letter (filed herewith). E-31-1 31b. Section 302 Certification Letter (filed herewith). E-31-2 32a. Section 906 Certification Letter (filed herewith). E-32-1 32b. Section 906 Certification Letter (filed herewith). E-32-2 ‡‡10pp. Squibb Corporation Deferral Plan for Fees of Outside Directors, as amended (as adopted, incorporated herein by reference to Exhibit 10e Squibb Corporation 1991 Form 10-K for the fiscal year ended December 31, 1987, File No. 1- 5514; as amended effective December 31, 1991 incorporated herein by reference to Exhibit 10m to the Form 10-K for the fiscal year ended December 31, 1992). 101. The following financial statements from the Bristol-Myers Squibb Company Annual Report on Form 10-K for the years ended December 31, 2018, 2017 and 2016, formatted in Extensible Business Reporting Language (XBRL): (i) consolidated statements of earnings, (ii) consolidated statements of comprehensive income, (iii) consolidated balance sheets, (iv) consolidated statements of cash flows, and (v) the notes to the consolidated financial statements. ‡